Skip to main content

  • Treatment of Device-Related Thrombosis After Left Atrial Appendage Occlusion: Initial Experience With Low-Dose Apixaban

    • Posted: 07/01/2022
    • Author:

      Eduardo Flores-Umanzor, Pedro Cepas-Guillen, Ander Regueiro, Laura Sanchis, Felipe Unigarro, Salvatore Brugaletta, Marta Sitges, Manel Sabaté and Xavier Freixa

    • 2022CRM

    Abstract

    Background

    Left atrial appendage (LAA) closure devices require short-term postprocedural oral antithrombotic therapy (AT) to prevent device-related thrombosis (DRT) until device endothelialization occurs. Currently, there is no consensus regarding the optimal AT strategy for DRT prevention.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details